LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure
Recruitment status was: Recruiting
|Lung Diseases, Obstructive Chronic Heart Failure Chronic Hypoxemia||Other: LTOT (oxygen therapy) Other: Pharmacological therapy of COPD and CHF||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF)|
- The primary outcome of the study is mortality. [ Time Frame: 3 years ]
- Secondary endpoint of the study is to evaluate whether the appropriate medical treatment without LTOT is not inferior to medical treatment with LTOT in terms of quality of life, rate and severity of exacerbation, number of hospital admissions. [ Time Frame: 3 years ]
|Study Start Date:||May 2008|
|Estimated Study Completion Date:||October 2012|
|Estimated Primary Completion Date:||March 2012 (Final data collection date for primary outcome measure)|
Study group: optimal medical therapy plus LTOT = or > 15 hours pro die
Other: LTOT (oxygen therapy)
Patients on LTOT will receive oxygen for at least 15 hours/day from the liquid oxygen systems at a flow rate adjusted to raise resting SaO2 between 93 and 96% and / or PaO2 between 65 and 80 mmHg every day for 3 years.
Other Name: LTOT treatment
Non LTOT group
control group: optimal medical therapy without LTOT
Other: Pharmacological therapy of COPD and CHF
Optimal pharmacologic treatment will include :
The treatment of the deseases will follow the international guidelines.
Other Name: Pharmacological treatment
Long-term oxygen treatment (LTOT) improves survival of COPD patients with severe hypoxemia . The improved survival was proven in COPD patients with severe chronic hypoxemia (PaO2< or = 55 mmHg), providing oxygen was delivered for = or >15 hours/day. Since then, > 15 hours/day LTOT has become the standard treatment for COPD patients with severe hypoxemia. LTOT has been extended without evidence to COPD patients with moderate hypoxemia (55< PaO2 <60mmHg), when associated with some clinical and laboratory signs of cardiac diseases and to patients with decreased oxygen saturation (SO2 < 90%) during exercise or sleep. Chronic heart failure (CHF) is a common co-morbidity of COPD (>30% ) particularly in the elderly. Whether LTOT improves survival in patients with moderate chronic hypoxemia and CHF is unknown. This is an issue of concern because of the potential importance of LTOT in severe COPD, and of the cost of LTOT (about Euro 250 millions/year in Italy). The aim of this 3 year randomized clinical trial is to investigate whether, in COPD patients with moderate hypoxemia associated with CHF treatment including LTOT is no different from treatment without LTOT in term of survival and of exacerbations, hospitalizations, and quality of life. The study will be conducted in 76 Italian hospital pulmonary units, and will start on May 15th 2008 and end on October 31st 2012. One thousand stable COPD patients treated according to COPD and CHF international guidelines will be randomized to treatment including LTOT (Study Group) or treatment without LTOT (Control Group). All patients will regularly undergo clinical assessment, arterial blood gases (3 monthly), and Saint George's Respiratory Questionnaire (SGRQ, 6 monthly),and will be contacted with monthly telephone calls.
Considering 1) the lack of evidence supporting LTOT in COPD patients with moderate hypoxemia and CHF, 2) the pathophysiology of CHF , and 3) the improvement of pharmacological treatment of both COPD and CHF, we expect that, after optimization of medical therapy, LTOT will not improve survival or frequency and severity of exacerbations and/or hospitalization, and not even quality of life due to the balance of small clinical benefits (improved exercise tolerance, better sleep) with the inconveniences associated with LTOT. This non-inferiority study is powered on survival, which is the primary outcome of the study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00668408
|Contact: Antonio Corrado, MD||39-055-794-6559 ext email@example.com|
|Contact: Teresa Renda, MD, PhDfirstname.lastname@example.org|
Show 66 Study Locations
|Principal Investigator:||Antonio Corrado, MD||AOU Careggi|